Compare Kaltura Inc (KLTR) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs Novartis AG — how do they compare? Kaltura Inc trades at $1.32 (market cap $199.08M), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 1349.1× Kaltura Inc's market cap, and Novartis AG pays a 3.31% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kaltura Inc for 21 Days and Novartis AG for 82 Days on average.
| KLTR | NVS | |
|---|---|---|
Market Cap | $199.08M | $268.57B |
Volume | 175,927 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $1.89 | $168.62 |
52-Week Low | $1.08 | $121.80 |
Typical Hold Time | 21 Days | 82 Days |
Enterprise Value | $211.29M | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kaltura (KLTR) trades at $1.305, down 1.88% with bearish technical signals. The company shows improving fundamentals with revenue stabilizing around $181M and narrowing losses, though still unprofitable. Recent positive developments include AI platform recognition and major streaming contracts, while valuation metrics remain elevated with P/S of 1.08 and EV/EBITDA of 271.59.
The outlook balances AI growth potential against persistent profitability challenges. Analyst consensus leans positive with 44% buy ratings, but high debt levels and negative cash flow present execution risks. The stock's direction hinges on AI monetization success and path to sustainable profitability.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
